Clinical Trial: SET-101

Trial Status: Open
Disease Type: Multiple Hematologic
Trial ID SET-101
Sponsor ID Epizyme, Inc.

A Phase 1/1b, Open-Label Multi Center Two Part Study of SETD2 Inhibitor EZM414 in Subjects with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma


Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID ERAS-007-04

A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Hematologic Malignancies (HERKULES-4).

Trial ID 21469
Sponsor ID LOTIS 9

A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)

Principal Investigator
Mitul Gandhi, MD